Streetbeat News

Analyst Ratings

HALO

Goldman Sachs analyst Graig Suvannavejh has downgraded Halozyme Therapeutics from Buy to Neutral, while raising the price target from $43 to $45.

Portfolio Pulse from richadhand@benzinga.com

July 24, 2023 | 8:49 am

SUM

Exane BNP Paribas analyst Paul Roger has downgraded Summit Materials (NYSE:SUM) from Outperform to Neutral and set a price target of $38.

Portfolio Pulse from richadhand@benzinga.com

July 24, 2023 | 8:48 am

SLB

Raymond James analyst James Rollyson has maintained an 'Outperform' rating on Schlumberger Limited (NYSE:SLB) and raised the price target from $65 to $67.

Portfolio Pulse from richadhand@benzinga.com

July 24, 2023 | 8:40 am

KNX

Raymond James analyst Patrick Tyler Brown maintains an Outperform rating on Knight-Swift (NYSE:KNX) and raises the price target from $57 to $60.

Portfolio Pulse from richadhand@benzinga.com

July 24, 2023 | 8:39 am

JNJ

Raymond James analyst Jayson Bedford maintains an Outperform rating on Johnson & Johnson (NYSE:JNJ) and raises the price target from $181 to $184.

Portfolio Pulse from richadhand@benzinga.com

July 24, 2023 | 8:37 am

ISRG

Raymond James analyst Jason Bednar maintains an 'Outperform' rating on Intuitive Surgical (NASDAQ:ISRG) and raises the price target from $323 to $368.

Portfolio Pulse from richadhand@benzinga.com

July 24, 2023 | 8:36 am

HBAN

Raymond James analyst David Long has maintained a 'Strong Buy' rating on Huntington Bancshares (NASDAQ:HBAN) and raised the price target from $14 to $15.

Portfolio Pulse from richadhand@benzinga.com

July 24, 2023 | 8:35 am

EVTC

Raymond James analyst John Davis has maintained an Outperform rating on Evertec (NYSE:EVTC) and raised the price target from $43 to $49.

Portfolio Pulse from richadhand@benzinga.com

July 24, 2023 | 8:34 am

CMA

Raymond James analyst Michael Rose has maintained a 'Strong Buy' rating on Comerica (NYSE:CMA) and raised the price target from $53 to $57.

Portfolio Pulse from richadhand@benzinga.com

July 24, 2023 | 8:33 am

SNA

Barrington Research analyst Gary Prestopino has reiterated an Outperform rating on Snap-on (NYSE:SNA) and maintained a price target of $325.

Portfolio Pulse from richadhand@benzinga.com

July 24, 2023 | 8:29 am